Pre-made Epcoritamab benchmark antibody ( Bispecific mAb, anti-CD3E;MS4A1/CD20 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-189
Awaiting product image

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-189 Category Tags ,

For more than 100mg, click here for inquiry. >>

inquire

Product Details

Pre-Made Epcoritamab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Envafolimab is a novel, single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant.

Products Name (INN Index)

Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1 therapeutic antibody
INN Name

Epcoritamab
Target

CD3E,MS4A1
Format

Bispecific mAb
Derivation

Bispecific antibody
Species Reactivity

Human
CH1 Isotype

IgG1
VD LC

Lambda,Kappa
Highest_Clin_Trial (Jan '20)

Phase-III
Est. Status

Active
100% SI Structure

None;None
99% SI Structure

None;None
95-98% SI Structure

None;3giz:HL/6y92:BA:HL
Year Proposed

2019
Year Recommended

2020
Companies

Genmab
Conditions Approved

NA
Conditions Active

Haematological malignancies,Diffuse large B-cell lymphoma,Chronic lymphocytic leukaemia,Follicular lymphoma,Non-Hodgkin's lymphoma
Conditions Discontinued

NA
Development Tech

NA
Previous Name

NA
Gm Offical Target Name

CD3E,MS4A1
Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide